When does a melanoma metastasize? Implications for management
- PMID: 38870033
- PMCID: PMC11174830
- DOI: 10.18632/oncotarget.28591
When does a melanoma metastasize? Implications for management
Abstract
Selecting which patients with clinically-localized melanoma require treatment other than wide excision of the primary tumor is based on the risk or presence of metastatic disease. This in turn is linked to survival. Knowing if and when a melanoma is likely to metastasize is therefore of great importance. Several studies employing a range of different methodologies have suggested that many melanomas metastasize long before the primary lesion is diagnosed. Therefore, waiting for dissemination of metastatic disease to become evident before making systemic therapy available to these patients may be less effective than giving them post-operative adjuvant therapy initially if the metastatic risk is high. The identification of these high-risk patients will assist in selecting those to whom adjuvant systemic therapy can most appropriately be offered. Further studies are required to better identify high-risk patients whose primary melanoma is likely to have already metastasized.
Keywords: adjuvant systemic therapy; melanoma; metastasis; time; tumor doubling time.
Conflict of interest statement
JFT has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Biopharmaceuticals, and travel and conference support from GSK, Provectus Biopharmaceuticals and Novartis. GJW has no conflicts of interest to declare.
Figures
References
-
- Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, et al., and KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022; 399:1718–29. 10.1016/S0140-6736(22)00562-1. - DOI - PubMed
-
- Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, et al.. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023; 29:2835–43. 10.1038/s41591-023-02583-2. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical